By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Repros Therapeutics Inc. 

2408 Timberloch Place
Suite B-7
The Woodlands  Texas  77380  U.S.A.
Phone: 281-719-3400 Fax: 281-719-3446


SEARCH JOBS








Company News
Repros Therapeutics (RPRX) Boss Steps Down, Interim CEO Named 2/2/2017 8:09:36 AM
Repros Therapeutics (RPRX) Release: FDA Grants End Of Phase 2 Meeting To Discuss Phase 3 Requirements For Oral Proellex In The Treatment Of Uterine Fibroids 1/31/2017 8:42:23 AM
Repros Therapeutics (RPRX) Requests Meeting With FDA To Discuss Phase 3 Requirements For Proellex In The Treatment Of Endometriosis 12/20/2016 10:02:45 AM
Repros Therapeutics (RPRX) Requests Meeting With FDA To Discuss Phase III Requirements For Proellex In The Treatment Of Symptomatic Uterine Fibroids 12/13/2016 7:48:59 AM
Repros Therapeutics (RPRX) Release: FDA Advisory Committee Discusses Clinical Trial Designs for Obesity-Related Hypogonadism 12/7/2016 8:08:26 AM
Repros Therapeutics (RPRX) Reports Topline Positive Clinical Data After Two 18 Week Courses Of Proellex Delivered Orally And Vaginally For The Treatment Of Uterine Fibroids 11/15/2016 10:47:15 AM
Repros Therapeutics (RPRX) Reports Third Quarter 2016 Financial Results 11/9/2016 8:38:15 AM
Repros Therapeutics (RPRX) Announces Acceptance Of Dossier For Enclomiphene For Secondary Hypogonadism By European Authorities 10/6/2016 7:30:16 AM
Repros Therapeutics (RPRX) Release: FDA Schedules Advisory Committee Meeting To Discuss Secondary Hypogonadism 9/26/2016 7:47:38 AM
Repros Therapeutics (RPRX) Announces Submission Of MAA To The EMA For Enclomiphene In The Treatment Of Secondary Hypogonadism 9/13/2016 10:05:38 AM
12345678910...
//-->